It suggested that combination of gemcitabine with autophagy promoter (like Vit D) in the patients with high ER expression, or with autophagy inhibitor (like hydroxylchloroquine) in patients with negative/low ER expression will be a feasible strategy that may have clinical significance for breast cancer patients with gemcitabine treatment. The gene discussed is ESR1; the disease is breast carcinoma.